National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Atezolizumab (Tecentriq®) HTA ID: 20039

Atezolizumab monotherapy is indicated as treatment of locally advanced or metastatic urothelial carcinoma (LaMUC) in adult patients who are considered cisplatin-ineligible and whose tumours have PD-L1 expression ≥5%.


NCPE Assessment Process Complete
Rapid review commissioned 17/08/2020
Rapid review completed 23/09/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations July 2021.